News Oculis takes second eye disease therapy into pivotal trials Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.
News Ozempic patient blinded by NAION sues Novo Nordisk Novo Nordisk has seen its first lawsuit over the proposed link between Ozempic and the rare eye disorder NAION.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.